Nefiracetam 77191-36-7
Product Description
.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}
Molecular Weight:
246.3 Nefiracetam is a GABAergic, cholinergic, and monoaminergic neuronal system enhancer for Ro 5-4864-induced convulsions. Phase 2.
Biological Activity
Nefiracetam at a concentration of 1 μM increases a long-lasting
component of calcium channel currents two-fold without affecting a
transient component. Nefiracetam induces a short-term
depression of ACh-evoked currents at submicromolar concentrations
(0.01–0.1 μM) and a long-term enhancement of the currents at micromolar
concentrations (1–10 μM).
Nefiracetam interacts with PKA and PKC
pathways, which may explain a cellular mechanism for the action of
cognition-enhancing agents. Lower (submicromolar) concentrations of the
nootropic Nefiracetam reduces ACh-evoked currents to 30% (0.01 μM) and
38% (0.1 μM) of control after a 10-minute treatment In
primary cultures of rat hippocampal neurons, nefiracetam increases the
rate of nicotine-sensitive miniature excitatory postsynaptic currents.
Nefiracetam induces a long-lasting facilitation of synaptic transmission
in both the CA1 area and the dentate gyrus of rat hippocampal slices,
and the facilitation is inhibited by α-bungarotoxin and mecamylamine.
Nefiracetam enhances activity of nicotinic ACh receptors by interacting
with a PKC pathway, thereby increasing glutamate release from
presynaptic terminals, and then leading to a sustained facilitation of
hippocampal neurotransmission.
Nefiracetam administered orally inhibits Ro 5-4864-induced convulsions
in EL mice. Nefiracetam also efficiently inhibits Ro 5-4864-induced
convulsions in DDY mice at doses higher than 10 mg/kg. Nefiracetam administered daily 1 hour before each training session
facilitates the acquisition process of the avoidance response.
Contact us if you need more details on 77191-36-7. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Nefiracetam 77191-36-7、77191-36-7 Nefiracetam. If these products fail to match your need, please contact us and we would like to provide relevant information.
Molecular Weight:
246.3 Nefiracetam is a GABAergic, cholinergic, and monoaminergic neuronal system enhancer for Ro 5-4864-induced convulsions. Phase 2.
Biological Activity
Nefiracetam at a concentration of 1 μM increases a long-lasting
component of calcium channel currents two-fold without affecting a
transient component. Nefiracetam induces a short-term
depression of ACh-evoked currents at submicromolar concentrations
(0.01–0.1 μM) and a long-term enhancement of the currents at micromolar
concentrations (1–10 μM).
Nefiracetam interacts with PKA and PKC
pathways, which may explain a cellular mechanism for the action of
cognition-enhancing agents. Lower (submicromolar) concentrations of the
nootropic Nefiracetam reduces ACh-evoked currents to 30% (0.01 μM) and
38% (0.1 μM) of control after a 10-minute treatment In
primary cultures of rat hippocampal neurons, nefiracetam increases the
rate of nicotine-sensitive miniature excitatory postsynaptic currents.
Nefiracetam induces a long-lasting facilitation of synaptic transmission
in both the CA1 area and the dentate gyrus of rat hippocampal slices,
and the facilitation is inhibited by α-bungarotoxin and mecamylamine.
Nefiracetam enhances activity of nicotinic ACh receptors by interacting
with a PKC pathway, thereby increasing glutamate release from
presynaptic terminals, and then leading to a sustained facilitation of
hippocampal neurotransmission.
Nefiracetam administered orally inhibits Ro 5-4864-induced convulsions
in EL mice. Nefiracetam also efficiently inhibits Ro 5-4864-induced
convulsions in DDY mice at doses higher than 10 mg/kg. Nefiracetam administered daily 1 hour before each training session
facilitates the acquisition process of the avoidance response.
Contact us if you need more details on 77191-36-7. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Nefiracetam 77191-36-7、77191-36-7 Nefiracetam. If these products fail to match your need, please contact us and we would like to provide relevant information.
Product Categories : Transmembrane Transporters > GABA Receptor Inhibitor
Premium Related Products
Other Products
Hot Products
Astragaloside AChlortetracycline HCl 64-72-2Paclitaxel 33069-62-4Dexamethasone Acetate 1177-87-3Dinaciclib (SCH727965) 779353-01-4CHIR-124 405168-58-3Ro3280 1062243-51-9TAME 901-47-3CCG-1423 285986-88-110058-F4 403811-55-2Dabigatran (BIBR 953) 211914-51-1H 89 2HCl 130964-39-5T0901317 293754-55-9Aprepitant 170729-80-3Turofexorate Isopropyl (XL335) 629664-81-9BMS-378806 357263-13-9